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Abstract
Case reports have linked childhood nephrotic syndrome to food sensitivity, including gluten. We 
report our experience with 8 children (6 boys, 2 girls; age at implementation of special diet 2–14 
years) with difficult-to-manage nephrotic syndrome who were placed on a gluten-free diet for 3.4 
± 4.3 years (range, 0.6–14 years) and who had clinical improvement enabling reduction or 
discontinuation in steroid dosage.
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Nephrotic syndrome (NS) is a rare condition in childhood that presents with proteinuria, 
hypoalbuminemia, and edema. Kidney function is usually normal. Most children (>90%) 
respond to an initial course of oral steroids and are designated as having steroid-sensitive 
NS. These children are presumed to have minimal change disease and typically do not 
undergo a confirmatory kidney biopsy.1 However, ~30% to 50% of patients have difficult-to-
manage disease characterized by steroid dependence or frequent relapses. A smaller 
percentage will fail to respond to an initial course of steroids and are considered to have 
steroid-resistant NS. Patients with difficult-to-manage NS are often treated with 
immunosuppressive medications to alleviate debilitating side effects due to prolonged 
steroid therapy or sequelae of uncontrolled NS such as infection.2 However, these second-
line agents also have significant side effects and/or are nephrotoxic. There is an urgent need 
to develop novel therapeutic approaches to frequently relapsing, steroid-dependent, or 
steroid-resistant NS that are safe and well tolerated and which can achieve extended 
remission of proteinuria.
Over the last 40 years, case reports and patient series have been published that describe the 
impact of food sensitivity and alterations in the diet to control NS in pediatric and adult 
patients.3–7 Most patients were presumed to have sensitivity to cow’s milk, and intervention 
focused on implementation of a milk-free or otherwise restricted diet. Removal of these 
dietary antigens resulted in resolution of NS. Lagrue et al5 reported the largest experience 
comprising 42 subjects with difficult-to-manage NS. Use of an oligoantigenic diet, which 
seems to have excluded gliadin, in 13 patients resulted in >50% reduction (median decrease, 
90%) in proteinuria in the majority of cases and complete remission in 5 cases. The response 
was rapid (within 1 week in most cases), and proteinuria recurred immediately in most 
responsive patients when the restricted diet was stopped. In a subset of patients with NS, 
long-term steroid-free remissions were achieved by more specific dietary elimination, 
including elimination of gluten.5 These observations suggest that gluten sensitivity may 
contribute to disease in select cases of childhood NS.
A group of pediatric nephrologists compiled their experience with difficult-to-manage NS in 
a nonrandom cohort of patients whose clinical behavior was ameliorated after starting a 
gluten-free diet. This series is the largest to date documenting the efficacy of this 
nonpharmacologic approach to treating NS in children or adults.
METHODS
Patients with steroid-sensitive NS with a steroid-dependent or frequently relapsing pattern or 
steroid-resistant NS who were treated with a gluten-free diet were identified at the 
participating pediatric nephrology centers. The patients received medical care at several 
medical centers, and the treatment of NS was not standardized. In general, patients did not 
undergo a kidney biopsy at presentation and were initially treated with daily steroids 
followed by alternate-day steroids, based on the protocol implemented at each site to 
manage the first presentation of NS. Relapses were treated with daily prednisone until the 
patients achieved remission followed by an interval of alternate-day therapy with or without 
taper, as per the local treatment regimen. Both steroid-dependent and steroid-resistant 
disease were treated with a variety of immunosuppressive agents. Remission was defined as 
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a dipstick test result of negative or trace in a first morning urine sample for 3 consecutive 
days. Relapse was defined as a dipstick test result of 3+ or more or a protein/creatinine ratio 
>2.0 mg/mg in a first morning urine sample in children with edema or 2+ or more for 3 
consecutive days in children without edema. The definitions of the International Study of 
Kidney Diseases in Children regarding steroid dependence (relapse of proteinuria while 
receiving alternate-day steroids or within 2 weeks of discontinuation of the drug), frequently 
relapsing NS (≥2 relapses in the initial 6 months of disease or ≥4 relapses in any 12-month 
period), or steroid resistance (failure to respond to an initial 4- to 6-week course of steroids) 
were generally applied to the characterization of the study patients.8
The gluten-free diet was selected as a course of therapy by the medical team or the family 
and patient. Initial education about a gluten-free diet was conducted in consultation with a 
nutritionist in select cases. The gluten-free diet was implemented by the family in the home 
setting with no in-home supervision from medical staff or a renal nutritionist. Adherence to 
the diet was voluntary and was not assessed in a systematic manner.
The study was reviewed and determined not to be subject to regulation by participating 
center institutional review boards.
CASE REPORT
An 11-year-old boy (case no. 2) had onset of NS at age 7 years. Although he was responsive 
to oral corticosteroids, he relapsed during the initial course of therapy and was eventually 
treated with oral cyclophosphamide (total cumulative dose, 168 mg/kg). A kidney biopsy 
was performed 10 months into his course of treatment and demonstrated minimal change 
disease, immunoglobulin (Ig) M variant. There was no histopathologic evidence of focal 
segmental glomerulosclerosis. At that time, he was being maintained on alternate-day oral 
steroids to prevent persistent relapses. Shortly after his biopsy, his parents elected to start 
him on a gluten-free diet. With the exception of a brief, self-limited relapse (precipitated by 
ingestion of a cupcake), the patient has been without any relapses and off all therapy, and he 
continues to follow the gluten-free diet over 4 years later.
The clinical features of this patient and the remaining 7 cases are summarized in Table 1.
DISCUSSION
To the best of our knowledge, this case series represents the largest cohort of patients, 
pediatric or adult, with frequently relapsing, steroid-dependent, or steroid-resistant NS who 
have been treated with a gluten-free diet and demonstrates a favorable impact on the course 
of their NS. All patients experienced a significant reduction in the relapse rate from the year 
before the change in diet compared with the period when they were maintained on the 
gluten-free diet. Moreover, in each case, the attending nephrologist was able to lower the 
dose or discontinue steroid use and other immunosuppressive medications. The beneficial 
impact of the gluten-free diet was reinforced by the relapses and recurrence of a steroid-
dependent course that occurred in some cases in association with documented re-exposure to 
gluten. None of the patients reported any significant side effects while on the gluten-free 
diet.
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Celiac disease (CD), the classic gastrointestinal manifestation of gluten sensitivity, occurs in 
1% of the population.9 Renal disease, including mesangial IgA deposition without clinically 
overt IgA nephropathy, has been described in patients with CD.10 In patients with IgA 
nephropathy, gluten induces alterations in intestinal immunity and barrier function.11 
Withdrawal of gluten from the diet of some individuals with glomerular disease such as IgA 
nephropathy with NS is reportedly associated with resolution of both CD and renal 
manifestations.12
We are unable to elucidate the mechanism of action of the gluten-free diet in the children 
with difficult-to-manage NS. However, gluten restriction could affect NS in several ways. 
First, there may be an alteration in the intestinal microbiome leading to changes in the 
release of inflammatory mediators that are responsible for increasing glomerular 
permeability to protein.3 Second, there may be a direct effect of the gluten-free diet on 
podocyte structure. Primary childhood NS, which is predominantly due to either minimal 
change disease or focal segmental glomerulosclerosis, represents a podocytopathy, in which 
abnormalities in the glomerular visceral epithelial cell result in increased permeability to 
protein.13 CD is characterized by loss of the intestinal epithelial barrier function.14 
Circulating levels of zonulin, a protein that is implicated in the pathogenesis of CD, are 
elevated in CD and reduced upon instituting a gluten-free diet.15, 16 Mechanistically, zonulin 
activates protease-activated receptor 2 (PAR2), a member of the G-protein–coupled receptor 
family, and induces signaling events that lead to changes in the actin cytoskeleton and cell–
cell junctions.17 PAR2 is expressed on podocytes, and the gluten-induced elevation in serum 
zonulin levels may influence the interaction between PAR2 and protease-activated receptor 
3, which has been implicated in cell signaling and podocyte structure and function.18, 19 We 
propose that implementation of a gluten-free diet may stabilize the podocyte actin 
cytoskeleton and have a favorable impact on the clinical course of children with difficult-to-
manage NS through its effects on the zonulin–PAR2 axis.
Our study has several important limitations, including its retrospective design. The patients 
were self-selected on the basis of their willingness to implement the dietary change. Thus, 
the case series may have a bias toward reporting responders and not patients in whom the 
intervention failed. The gluten-free diet was self-administered, and we were thus unable to 
ascertain adherence to the diet. There was no consistent laboratory monitoring of serologic 
markers of CD, although how informative these data might be in this particular 
manifestation of gluten sensitivity is currently unknown. Information is unavailable to fully 
assess the impact of this change on growth, weight, blood pressure, or quality of life. 
However, gluten-free diets are followed in patients with CD with a normal growth pattern. 
Finally, children with frequently relapsing NS can achieve a spontaneous remission at any 
time and, therefore, we cannot draw definitive conclusions about the efficacy of the gluten-
free diet in the study patients without a controlled clinical trial.
CONCLUSIONS
This case series suggests that in a subset of children with difficult-to-manage NS, a 
relatively simple and safe intervention namely, elimination of gluten from the diet, may 
reduce the need for potentially toxic immunosuppressant therapies. Prospective studies are 
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needed to confirm the efficacy of a gluten-free diet in childhood NS, to investigate 
biomarkers that could identify those patients who are most likely to benefit from this novel 
therapy, and to clarify the mechanism of action. The growing use of and greater access to 
gluten-free food items underscore the feasibility of this approach.
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